• The effect of beta-blockers on placental and fetal blood flow in pregnant women with high risk

The effect of beta-blockers on placental and fetal blood flow in pregnant women with high risk

PERINATOLOGIYA I PEDIATRIYA. 2016.4(68):15-18; doi 10.15574/PP.2016.68.15 
 

The effect of beta-blockers on placental and fetal blood flow in pregnant women with high risk


Davydova I. V., Limanskaya A. Yu.

SI «Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine», Kyiv


Purpose — to study the effect of the selective beta-blocker Biprolol («Borschagovsky CPP», Ukraine) on placental and fetal blood flow in pregnant women with arterial hypertension.


Patients and methods. The drug Biprolol («Borschagovsky CPP», Ukraine) was prescribed with anti-hypertensive purpose, the dosage is 5 mg once a day. The study included 27 pregnant women (main group) with arterial hypertension 1 and 2 degrees of severity with the highest level of blood pressure before the start of antihypertensive therapy not higher than 160/90 mm Hg. Of all studied women at the time of treatment initiation were absent statistically significant proteinuria, and growth retardation of the fetus. All pregnant women included in the study received treatment at least 6–8 weeks. The control group consisted of 20 patients who received the treatment of hypertension drug methyldopa in standard dosages. The healthy group consisted of 20 pregnant women.


Results. In the main group of pregnant receiving Biprolol («Borschagovsky CPP», Ukraine), significantly higher was the effectiveness of antihypertensive therapy, which allowed to prolong pregnancy until 37–39 weeks. In both groups no statistically significant changes in the structure of the placenta and fetometry compared to healthy pregnant women. The average IP in the arteries of the umbilical cord, uterine artery, and in the middle cerebral artery did not differ between studied groups of women (p>0.05) and corresponded to the norm those in healthy pregnant women.


Conclusions. Using the drug Biprolol («Borschagovsky CPP», Ukraine) in high-risk pregnant women with extragenital pathology provides a more soft and long-lasting antihypertensive effect. The obtained data prove the usefulness of the drug Biprolol («Borschagovsky CPP», Ukraine) as antihypertensive and antiarrhythmic agents, as well as the safety of their use in pregnant women.


Key words: beta-blockers, pregnancy, Biprolol.


References

1. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. 2007, Jan. Cochrane Database of Systematic Reviews. 24; 1: CD002252.

2. Calvert MJ, Shankar A, McManus RJ et al. 2009, Jan 18. Evaluation of the management of heart failure in primary care. Fam Pract. https://doi.org/10.1093/fampra/cmn105; PMid:19153098

3. Von Dadelszen P, Ornstein MP, Bull SB et al. 2000. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 355: 87—92. https://doi.org/10.1016/S0140-6736(98)08049-0

4. Von Dadelszen P, Ornstein MP, Bull SB et al. 2000. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 355; 9198: 87—92. https://doi.org/10.1016/S0140-6736(98)08049-0

5. Magee LA, Duley L. 2003. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database of Systematic Reviews. Is 3: Art No: CD002863. doi 10.1002/14651858.CD002863.

6. Wehling M. 2010. Multimorbidity and polypharmacy: which betablocker to use in relation to the pharmacokinetic profile and interaction potential. Arzneimittelforschung. 60(2): 57—63. PMid:20329652